ABCD1 and adrenoleukodystrophy: To assess its potential efficacy on ALD in vivo, 6–8-week-old male Abcd1 KO mice were dosed orally twice daily with PXL770 at 75 mg/kg for 8 weeks (n = 12 to 15 animals/condition).